A drug widely used to treat COVID-19 might be spurring the evolution of new SARS-CoV-2 variants. The drug, molnupiravir, works by introducing a flurry of mutations to the viral genome; this helps to ...

The antiviral molnupiravir may be shaping the evolution of the virus behind COVID-19, but we still don't know what this means for transmission or the emergence of variants. When you purchase through ...

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has ...

A drug used to treat covid-19 appears to be driving the evolution of the SARS-CoV-2 coronavirus, according to an analysis of the 15 million viruses sequenced around the world so far. The analysis ...

Weighing three outpatient treatments for COVID-19, the drug cost watchdog Institute for Clinical and Economic Review (ICER) has determined that Pfizer’s Paxlovid, Merck and Ridgeback Biotherapeutics’ ...

The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...

Last Thursday, the Food and Drug Administration made what may be the most momentous drug-approval decision in its history: It granted emergency-use authorization for Merck’s molnupiravir to treat ...

BENGALURU (Reuters) – Two Indian drugmakers have requested permission to end late-stage trials of their generic versions of Merck & Co’s promising experimental oral antiviral drug molnupiravir to ...

**Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022, Lisbon, 23-26 April). Please credit the conference if you ...

Pfizer wasn’t the only drugmaker to score an early Christmas present from the FDA this year. A day after Paxlovid’s blessing as the first oral COVID-19 treatment, Merck & Co. and Ridgeback ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that a total of approximately 3.1 million ...

Deal negotiated by U.N.-backed agency to expand output of drug Nearly 30 firms to sell low-cost molnupiravir in 105 nations Asian, African makers may sell at $20, no royalties for now BRUSSELS, Jan 20 ...